Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
暂无分享,去创建一个
M. Dowsett | D. Dearnaley | C. Parker | C. Cooper | S. Kaye | T. Yap | F. Raynaud | Jeremy Clark | J. D. de Bono | G. Attard | Gloria Lee | V. Martins | E. Folkerd | A. Reid | S. Settatree | M. Barrett